Literature DB >> 27619472

Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.

Robert Zeiser1, Gerard Socié2, Bruce R Blazar3.   

Abstract

Acute graft-versus-host disease (aGVHD) is a major life-threatening complication of allogeneic haematopoietic cell transplantation (allo-HCT). Here we discuss the aGVHD pathophysiology initiated by multiple signals that cause alloreactive T-cell activation. The outcome of such donor T-cell activation is influenced by T-cell receptor-signal strength, anatomical location, co-stimulatory/co-inhibitory signals and differentiation stage (naive, effector/memory) of T-cells. Additionally, cross-priming of T cells to antigens expressed by pathogens can contribute to aGVHD-mediated tissue injury. In addition to the properties of donor T-cell activation, highly specialized tissue resident cell types, such as innate lymphoid cells, antigen-presenting cells, immune regulatory cells and various intestinal cell populations are critically involved in aGVHD pathogenesis. The role of the thymus and secondary lymphoid tissue injury, non-haematopoietic cells, intestinal microflora, cytokines, chemokines, microRNAs, metabolites and kinases in aGVHD pathophysiology will be highlighted. Acute GVHD pathogenic mechanisms will be connected to novel therapeutic approaches under development for, and tested in, the clinic.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  danger associated molecular patterns; graft-versus-host disease; micro RNAs; neutrophils; novel targets

Mesh:

Substances:

Year:  2016        PMID: 27619472     DOI: 10.1111/bjh.14295

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  51 in total

Review 1.  Biology-driven developments in the therapy of acute graft-versus-host disease.

Authors:  Robert Zeiser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

3.  The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation.

Authors:  Bertrand Routy; Caroline Letendre; David Enot; Maxime Chénard-Poirier; Vikram Mehraj; Noémie Charbonneau Séguin; Khaled Guenda; Kathia Gagnon; Paul-Louis Woerther; David Ghez; Silvy Lachance
Journal:  Oncoimmunology       Date:  2016-12-27       Impact factor: 8.110

Review 4.  Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.

Authors:  Steven Naymagon; Leonard Naymagon; Serre-Yu Wong; Huaibin Mabel Ko; Anne Renteria; John Levine; Jean-Frederic Colombel; James Ferrara
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

Review 5.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

6.  ST2/MyD88 Deficiency Protects Mice against Acute Graft-versus-Host Disease and Spares Regulatory T Cells.

Authors:  Brad Griesenauer; Hua Jiang; Jinfeng Yang; Jilu Zhang; Abdulraouf M Ramadan; Jane Egbosiuba; Khaled Campa; Sophie Paczesny
Journal:  J Immunol       Date:  2019-04-12       Impact factor: 5.422

Review 7.  Gut microbiota and its implications in small bowel transplantation.

Authors:  Chenyang Wang; Qiurong Li; Jieshou Li
Journal:  Front Med       Date:  2018-03-09       Impact factor: 4.592

8.  MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function.

Authors:  Nina C Zitzer; Katiri Snyder; Xiamoei Meng; Patricia A Taylor; Yvonne A Efebera; Steven M Devine; Bruce R Blazar; Ramiro Garzon; Parvathi Ranganathan
Journal:  J Immunol       Date:  2018-05-02       Impact factor: 5.422

9.  Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.

Authors:  Lucie M Turcotte; Tao Wang; Michael T Hemmer; Stephen R Spellman; Mukta Arora; Ashley Yingst; Daniel Couriel; Amin Alousi; Joseph Pidala; Jennifer M Knight; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-23       Impact factor: 5.742

10.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.